168 related articles for article (PubMed ID: 31630373)
1. CDX2 Protein Expression in Colorectal Cancer and ItsCorrelation with Clinical and Pathological Characteristics, Prognosis, and Survival Rate of Patients.
Asgari-Karchekani S; Karimian M; Mazoochi T; Taheri MA; Khamehchian T
J Gastrointest Cancer; 2020 Sep; 51(3):844-849. PubMed ID: 31630373
[TBL] [Abstract][Full Text] [Related]
2. SOX2 expression is associated with a cancer stem cell state and down-regulation of CDX2 in colorectal cancer.
Lundberg IV; Edin S; Eklöf V; Öberg Å; Palmqvist R; Wikberg ML
BMC Cancer; 2016 Jul; 16():471. PubMed ID: 27411517
[TBL] [Abstract][Full Text] [Related]
3. Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer.
Zhang BY; Jones JC; Briggler AM; Hubbard JM; Kipp BR; Sargent DJ; Dixon JG; Grothey A
Clin Colorectal Cancer; 2017 Jun; 16(2):124-128. PubMed ID: 27726953
[TBL] [Abstract][Full Text] [Related]
4. Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location.
Ben-Aharon I; Goshen-Lago T; Sternschuss M; Morgenstern S; Geva R; Beny A; Dror Y; Steiner M; Hubert A; Idelevich E; Shulman K; Mishaeli M; Man S; Liebermann N; Soussan-Gutman L; Brenner B
Oncologist; 2019 Aug; 24(8):e696-e701. PubMed ID: 30755502
[TBL] [Abstract][Full Text] [Related]
5. Lymph node yield after colectomy for cancer: is absence of mismatch repair a factor?
Samdani T; Schultheis M; Stadler Z; Shia J; Fancher T; Misholy J; Weiser MR; Nash GM
Dis Colon Rectum; 2015 Mar; 58(3):288-93. PubMed ID: 25664706
[TBL] [Abstract][Full Text] [Related]
6. CDX2 downregulation is associated with poor differentiation and MMR deficiency in colon cancer.
Olsen J; Eiholm S; Kirkeby LT; Espersen ML; Jess P; Gögenür I; Olsen J; Troelsen JT
Exp Mol Pathol; 2016 Feb; 100(1):59-66. PubMed ID: 26551082
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of CDX2 and Villin Expression in Advanced Stage Colorectal Carcinoma.
Altintas S; Bayrak M; Altintas Y
J Coll Physicians Surg Pak; 2019 Nov; 29(11):1057-1061. PubMed ID: 31659962
[TBL] [Abstract][Full Text] [Related]
8. Up-regulation of cadherin 17 and down-regulation of homeodomain protein CDX2 correlate with tumor progression and unfavorable prognosis in epithelial ovarian cancer.
Huang LP; Yu YH; Sheng C; Wang SH
Int J Gynecol Cancer; 2012 Sep; 22(7):1170-6. PubMed ID: 22810971
[TBL] [Abstract][Full Text] [Related]
9. CDX2 and Muc2 immunohistochemistry as prognostic markers in stage II colon cancer.
Cecchini MJ; Walsh JC; Parfitt J; Chakrabarti S; Correa RJ; MacKenzie MJ; Driman DK
Hum Pathol; 2019 Aug; 90():70-79. PubMed ID: 31121192
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-inducible factor-1alpha modulates the down-regulation of the homeodomain protein CDX2 in colorectal cancer.
Zheng J; Sun X; Wang W; Lu S
Oncol Rep; 2010 Jul; 24(1):97-104. PubMed ID: 20514449
[TBL] [Abstract][Full Text] [Related]
11. Combination of CDX2 expression and T stage improves prognostic prediction of colorectal cancer.
Xu W; Zhu Y; Shen W; Ding W; Wu T; Guo Y; Chen X; Zhou M; Chen Y; Cui L; Du P
J Int Med Res; 2019 May; 47(5):1829-1842. PubMed ID: 30616445
[TBL] [Abstract][Full Text] [Related]
12. Expression of Cdx2 and hepatocyte antigen in gastric carcinoma: correlation with histologic type and implications for prognosis.
Fan Z; Li J; Dong B; Huang X
Clin Cancer Res; 2005 Sep; 11(17):6162-70. PubMed ID: 16144916
[TBL] [Abstract][Full Text] [Related]
13. Lymph node CXCL17 messenger RNA: A new prognostic biomarker for colon cancer.
Rashad Y; Olsson L; Israelsson A; Öberg Å; Lindmark G; Hammarström ML; Hammarström S; Sitohy B
Tumour Biol; 2018 Sep; 40(9):1010428318799251. PubMed ID: 30198422
[TBL] [Abstract][Full Text] [Related]
14. Quantitative analysis of CDX2 protein expression improves its clinical utility as a prognostic biomarker in stage II and III colon cancer.
den Uil SH; de Wit M; Slebos RJC; Delis-van Diemen PM; Sanders J; Piersma SR; Pham TV; Coupé VMH; Bril H; Stockmann HBAC; Jimenez CR; Meijer GA; Fijneman RJA
Eur J Cancer; 2021 Feb; 144():91-100. PubMed ID: 33341450
[TBL] [Abstract][Full Text] [Related]
15. Mismatch repair phenotype determines the implications of tumor grade and CDX2 expression in stage II-III colon cancer.
Hestetun KE; Aasebø K; Rosenlund NB; Müller Y; Dahl O; Myklebust MP
Mod Pathol; 2021 Jan; 34(1):161-170. PubMed ID: 32737450
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of total number of lymph nodes retrieved differs between left-sided colon cancer and right-sided colon cancer in stage III patients with colon cancer.
Yang L; Xiong Z; Xie Q; He W; Liu S; Kong P; Jiang C; Guo G; Xia L
BMC Cancer; 2018 May; 18(1):558. PubMed ID: 29751794
[TBL] [Abstract][Full Text] [Related]
17. Prospective multicenter trial of staging adequacy in colon cancer: preliminary results.
Bilchik AJ; DiNome M; Saha S; Turner RR; Wiese D; McCarter M; Hoon DS; Morton DL
Arch Surg; 2006 Jun; 141(6):527-33; discussion 533-4. PubMed ID: 16785352
[TBL] [Abstract][Full Text] [Related]
18. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study.
Bacman D; Merkel S; Croner R; Papadopoulos T; Brueckl W; Dimmler A
BMC Cancer; 2007 Aug; 7():156. PubMed ID: 17692120
[TBL] [Abstract][Full Text] [Related]
19. Lymph Node Micrometastasis Cannot Be Considered as Positive Lymph Node in Nonmetastatic Colorectal Cancer.
Hong KD; Um JW; Min BW; Ji WB; Choi JW; Kim YS
Am Surg; 2017 Feb; 83(2):127-133. PubMed ID: 28228198
[TBL] [Abstract][Full Text] [Related]
20. Analysis of clinicopathological features and prognosis of 1315 cases in colorectal cancer located at different anatomical subsites.
Feng Z; Shi X; Zhang Q; Zhang X; Li X; Chen Z; Liu D; Sun B; Zuo Y; Ren S
Pathol Res Pract; 2019 Oct; 215(10):152560. PubMed ID: 31375274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
